NanoLogix Inc (NNLX)

[Emerald Isle]

One MD's perspective on the potential on the Nanologix N-Assay Bacteria Diagnostic kit:

"If it becomes the Test of Choice/Best Available Technology, then it would be used over time on a large (perhaps all) percentage of the prenatal testing in the USA, 2015 live births were roughly 4,000,000

The selling point for a truly superior test in time and sensitivity could result in a higher cost for the actual test being justifiable over other tests if the end results lowered the amount the insurance companies ultimately paid out due to time savings, the ability to have the test performed in-house, and reduced complications to the patient & neonate due to the benefits of greater sensitivity, rapid results, and reduced dependence upon broad-spectrum antibiotics while awaiting results.

If the N-Assay initially captured only 15% of tests at $150/per test, that could be $90 million in revenue. Not too bad.

Many would argue that the market would not support that number, but you have to look at what the insurance companies pay and then it's obvious it can happen."

EI